These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 8271390)

  • 1. [Anti-HIV compounds].
    Kiso Y; Kisanuki S
    Nihon Rinsho; 1993 Sep; 51 Suppl():235-40. PubMed ID: 8271390
    [No Abstract]   [Full Text] [Related]  

  • 2. Turnabout on AIDS drug.
    Science; 1992 Jan; 255(5041):154. PubMed ID: 1553539
    [No Abstract]   [Full Text] [Related]  

  • 3. New AIDS drug poised to move into development.
    Science; 1991 Dec; 254(5039):1715. PubMed ID: 1763318
    [No Abstract]   [Full Text] [Related]  

  • 4. Differential effect of tumor necrosis factor-alpha and herpes simplex virus type 1 on the Tat-targeted inhibition of human immunodeficiency virus type 1 replication.
    Popik W; Pitha PM
    Virology; 1994 Aug; 202(2):521-9. PubMed ID: 8030218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic potential of Ro 5-3335. New active benzodiazepine in vitro against HIV-1 viruses resistant or non-resistant to AZT].
    Camsonne R; Bigot MC; Fusibet H; Moulin MA
    Therapie; 1993; 48(2):105-7. PubMed ID: 8351676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
    Connell EV; Hsu MC; Richman DD
    Antimicrob Agents Chemother; 1994 Feb; 38(2):348-52. PubMed ID: 7514858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments in antiretroviral drug therapy for HIV infection.
    Johnson VA
    AIDS Clin Rev; 1992; ():69-104. PubMed ID: 1318738
    [No Abstract]   [Full Text] [Related]  

  • 8. A Tat antagonist inhibits HIV-1 induction in naturally infected and experimentally infected T cells.
    Potash MJ; Bentsman G; McKinley G; Volsky DJ
    Biochem Biophys Res Commun; 1992 Nov; 189(1):250-6. PubMed ID: 1449479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Present status and future prospects for HIV therapies.
    Johnston MI; Hoth DF
    Science; 1993 May; 260(5112):1286-93. PubMed ID: 7684163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Phenylcoumarins as HIV transcription inhibitors.
    Bedoya LM; Beltrán M; Sancho R; Olmedo DA; Sánchez-Palomino S; del Olmo E; López-Pérez JL; Muñoz E; San Feliciano A; Alcamí J
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4447-50. PubMed ID: 16137881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival.
    Vlahakis SR; Bren GD; Algeciras-Schimnich A; Trushin SA; Schnepple DJ; Badley AD
    Clin Pharmacol Ther; 2007 Sep; 82(3):294-9. PubMed ID: 17361127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Glycineamide-5-chlorophenyl 2-pyrryl ketone, a non-benzodiazepin Tat antagonist, is effective against acute and chronic HIV-1 infections in vitro.
    Kira T; Hashimoto K; Baba M; Okamoto T; Shigeta S
    Antiviral Res; 1996 Oct; 32(2):55-62. PubMed ID: 8891164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Protease inhibitors are effective only on HIV-infected cells].
    Fortschr Med; 1996 May; 114(15):12. PubMed ID: 8767934
    [No Abstract]   [Full Text] [Related]  

  • 14. [HIV: to administer protease inhibitors early].
    Dtsch Med Wochenschr; 1996 Dec; 121(49):A49. PubMed ID: 8998916
    [No Abstract]   [Full Text] [Related]  

  • 15. [Targets and possible therapeutic interventions for HIV carriers].
    Kageyama S; Kurimura T
    Nihon Rinsho; 1993 Sep; 51 Suppl():351-6. PubMed ID: 8271402
    [No Abstract]   [Full Text] [Related]  

  • 16. [HIV-protease inhibitors: pros and cons].
    Briones C; Soriano V
    Med Clin (Barc); 1999 May; 112(18):702-5. PubMed ID: 10374204
    [No Abstract]   [Full Text] [Related]  

  • 17. AIDS-related lipodystrophy/insulin resistance syndrome.
    Kino T; Mirani M; Alesci S; Chrousos GP
    Horm Metab Res; 2003 Mar; 35(3):129-36. PubMed ID: 12734771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfated polymannuroguluronate, a novel anti-acquired immune deficiency syndrome drug candidate, blocks neuroinflammatory signalling by targeting the transactivator of transcription (Tat) protein.
    Hui B; Xia W; Li J; Wang L; Ai J; Geng M
    J Neurochem; 2006 Apr; 97(2):334-44. PubMed ID: 16539678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of tat-mediated HIV-1-LTR transactivation and virus replication by sulfhydryl compounds with chelating properties.
    Demirhan I; Chandra A; Sarin PS; Hasselmayer O; Hofmann D; Chandra P
    Anticancer Res; 2000; 20(4):2513-7. PubMed ID: 10953320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More clinical data on protease inhibitors.
    Smart T
    GMHC Treat Issues; 1995 Oct; 9(10):4-7. PubMed ID: 11362917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.